GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Degree of Operating Leverage

XERS (Xeris Biopharma Holdings) Degree of Operating Leverage : -1.86 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Xeris Biopharma Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -1.86. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Xeris Biopharma Holdings's Degree of Operating Leverage or its related term are showing as below:

XERS's Degree of Operating Leverage is ranked better than
78.77% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs XERS: -1.86

Xeris Biopharma Holdings Degree of Operating Leverage Historical Data

The historical data trend for Xeris Biopharma Holdings's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Degree of Operating Leverage Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only -0.05 0.31 -0.25 -1.12 -1.17

Xeris Biopharma Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -1.18 -0.38 -1.17 -1.86

Competitive Comparison of Xeris Biopharma Holdings's Degree of Operating Leverage

For the Biotechnology subindustry, Xeris Biopharma Holdings's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Degree of Operating Leverage falls into.


;
;

Xeris Biopharma Holdings Degree of Operating Leverage Calculation

Xeris Biopharma Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -16.893 (Mar. 2025) / -37.918 (Mar. 2024) - 1 )/( 222.551 (Mar. 2025) / 171.356 (Mar. 2024) - 1 )
=-0.5545/0.2988
=-1.86***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Xeris Biopharma Holdings  (NAS:XERS) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Xeris Biopharma Holdings Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings Business Description

Traded in Other Exchanges
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Executives
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015